NORTH AMERICA DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The market is segmented by the drug (Insulin, Oral anti-diabetic drugs, Non-Insulin Injectable drugs, and Combination Drugs) and geography.

Market Snapshot

North America diabetes market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: North America
North America diabetes market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • North America dominates the diabetes drugs care market globally, and the US holds the highest market share in the North America region. 
  • Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or does not produce insulin which is known as Type 1 diabetes, or because the body's cells do not respond appropriately to insulin which is called Type-2 diabetes mellitus, or both.
  • Approximately 10% of all diabetes cases are type-1, and about 90% of all cases of diabetes worldwide are of type-2.

Scope of the Report

For treating diabetes in the US and worldwide there are certain categories of drugs available which include: Combination drugs, Insulin, non-insulin injectables and oral antidiabetic drugs. Among all the categories oral antidiabetic drugs holds the major market share at a massive 40.06% followed by insulin which is 38%. The geographies covered in the report include US and Canada in the North America region.

By Product type Insulin Basal or Long Acting Insulins Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral anti-diabetic drugs Biguanides Metformin
Alpha-Glucosidase Inhibitors Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist Bromocriptin
SGLT2 inhibitors  Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP4 inhibitors Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas Sulfonylureas
Meglitinides Meglitinides
Non-Insulin Injectable drugs GLP1 receptor agonists Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue Symlin (Pramlintide)
Combination Drugs Insulin Combinations NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination Janumet (Sitagliptin and Metformin HCl)
By Geography North America United States
Canada
Rest of North America
 
 
By Product Type
Oral Drugs (Value and Volume, 2012-2024)
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Insulins (Value and Volume, 2012-2024)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs (Value and Volume, 2012-2024)
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs (Value and Volu, 2012-2024)
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Geography
North America (Value and Volume, 2012-2024)
United States
By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)
Canada
By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)
Rest of North America
By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Rising Prevalence of Diabetes

  • North America diabetes market size in 2019 was USD 33462.12 million with an expected CAGR of 6.19% during the forecast period 2018-2024.
  • The rising prevalence of diabetes in the United States is the most influencing factor driving the market for diabetes drugs in the region.
  • In 2017, 7.4% of the population of the United States, i.e., 24.18 million were diabetic. Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
  • With the increase in diabetes population, the need and demand for diabetes drugs are expected to increase in North America.
  • The other factors, such as better adoption than other therapies and government initiatives are driving the diabetes drugs market.
  • Canada also holds a significant share in the growth of the diabetic population with 3.4 million diabetic patients which comprise of 10.2% of the whole Canada population.
North America diabetes market Key Trends

The US leads the Market in the North America Region

  • The US diabetes drugs market holds the largest market share in 2017 in North America region where insulins hold the highest share of USD 10368 million which attributes to 41% of the total US market in diabetic drugs followed by oral anti-diabetic drug with 35.6%. 
  • Among the oral drugs, SGLT-2 and DPP-4 drugs market are highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. 
  • Factors like continuous updation of the label due to constant clinical trials will also lead to higher usage and growth in revenue.
North America diabetes market Growth by Region

Competitive Landscape

  • A large chunk of the diabetic population in the United States has been taking generic drugs during the past few years.
  • In 2017, per person, spending on diabetes drugs in the United States was more than any traditional medication. Half the prescribed drugs in this class were generics. Another cost concerning factor is seen in the Insulin market. There are no generic versions of the drug yet in the market though it is a very old invention.
  • While it is considered as a classical medication for diabetes, it is a costly affair for many people, which would eventually hinder the growth of the global diabetes drugs market.
  • The other factor, such as the regulatory framework and adverse reactions due to medications is also hindering the growth of the market.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

  5. 5. Porters Five Force Analysis

    1. 5.1 Threat of New Entrants

    2. 5.2 Bargaining Power of Buyers/Consumers

    3. 5.3 Bargaining Power of Suppliers

    4. 5.4 Threat of Substitute Products

    5. 5.5 Intensity of Competitive Rivalry

  6. 6. MARKET SEGMENTATION

    1. 6.1 By Product Type

      1. 6.1.1 Oral Drugs (Value and Volume, 2012-2024)

        1. 6.1.1.1 Biguanides

          1. 6.1.1.1.1 Metformin

        2. 6.1.1.2 Alpha-Glucosidase Inhibitors

          1. 6.1.1.2.1 Alpha-Glucosidase Inhibitors

        3. 6.1.1.3 Dopamine D2 receptor agonist

          1. 6.1.1.3.1 Bromocriptin

        4. 6.1.1.4 SGLT-2 inhibitors

          1. 6.1.1.4.1 Invokana (Canagliflozin)

          2. 6.1.1.4.2 Jardiance (Empagliflozin)

          3. 6.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

          4. 6.1.1.4.4 Suglat (Ipragliflozin)

        5. 6.1.1.5 DPP-4 inhibitors

          1. 6.1.1.5.1 Onglyza (Saxagliptin)

          2. 6.1.1.5.2 Tradjenta (Linagliptin)

          3. 6.1.1.5.3 Vipidia/Nesina(Alogliptin)

          4. 6.1.1.5.4 Galvus (Vildagliptin)

        6. 6.1.1.6 Sulfonylureas

          1. 6.1.1.6.1 Sulfonylureas

        7. 6.1.1.7 Meglitinides

          1. 6.1.1.7.1 Meglitinides

      2. 6.1.2 Insulins (Value and Volume, 2012-2024)

        1. 6.1.2.1 Basal or Long Acting Insulins

          1. 6.1.2.1.1 Lantus (Insulin Glargine)

          2. 6.1.2.1.2 Levemir (Insulin Detemir)

          3. 6.1.2.1.3 Toujeo (Insulin Glargine)

          4. 6.1.2.1.4 Tresiba (Insulin Degludec)

          5. 6.1.2.1.5 Basaglar (Insulin Glargine)

        2. 6.1.2.2 Bolus or Fast Acting Insulins

          1. 6.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 6.1.2.2.2 Humalog (Insulin Lispro)

          3. 6.1.2.2.3 Apidra (Insulin Glulisine)

        3. 6.1.2.3 Traditional Human Insulins

          1. 6.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 6.1.2.3.2 Humulin

          3. 6.1.2.3.3 Insuman

        4. 6.1.2.4 Biosimilar Insulins

          1. 6.1.2.4.1 Insulin Glargine Biosimilars

          2. 6.1.2.4.2 Human Insulin Biosimilars

      3. 6.1.3 Combination drugs (Value and Volume, 2012-2024)

        1. 6.1.3.1 Insulin combinations

          1. 6.1.3.1.1 NovoMix (Biphasic Insulin Aspart)

          2. 6.1.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 6.1.3.1.3 Xultophy (Insulin Degludec and Liraglutide)

        2. 6.1.3.2 Oral Combinations

          1. 6.1.3.2.1 Janumet (Sitagliptin and Metformin)

      4. 6.1.4 Non-Insulin Injectable drugs (Value and Volu, 2012-2024)

        1. 6.1.4.1 GLP-1 receptor agonists

          1. 6.1.4.1.1 Victoza (Liraglutide)

          2. 6.1.4.1.2 Byetta (Exenatide)

          3. 6.1.4.1.3 Bydureon (Exenatide)

          4. 6.1.4.1.4 Trulicity (Dulaglutide)

          5. 6.1.4.1.5 Lyxumia (Lixisenatide)

        2. 6.1.4.2 Amylin Analogue

          1. 6.1.4.2.1 Symlin (Pramlintide)

    2. 6.2 Geography

      1. 6.2.1 North America (Value and Volume, 2012-2024)

        1. 6.2.1.1 United States

          1. 6.2.1.1.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)

          2. 6.2.1.1.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)

        2. 6.2.1.2 Canada

          1. 6.2.1.2.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)

          2. 6.2.1.2.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)

        3. 6.2.1.3 Rest of North America

          1. 6.2.1.3.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)

          2. 6.2.1.3.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)

  7. 7. MARKET INDICATORS

    1. 7.1 Type-1 Diabetes population (2012-2024)

    2. 7.2 Type-2 Diabetes population (2012-2024)

  8. 8. COMPETITIVE LANDSCAPE

    1. 8.1 COMPANY PROFILES

      1. 8.1.1 Novo Nordisk A/S

      2. 8.1.2 Sanofi Aventis

      3. 8.1.3 Eli Lilly

      4. 8.1.4 Astra Zeneca

      5. 8.1.5 Bristol Myers Squibb

      6. 8.1.6 Boehringer Ingelheim

      7. 8.1.7 Mylan

      8. 8.1.8 Pfizer

      9. 8.1.9 Janssen Pharmaceuticals

      10. 8.1.10 Merck

      11. 8.1.11 Astellas

      12. 8.1.12 Teva

      13. 8.1.13 Takeda

      14. 8.1.14 Bayer

      15. 8.1.15 Sun Pharma

    2. *List Not Exhaustive
    3. 8.2 COMPANY SHARE ANALYSIS

      1. 8.2.1 Novo Nordisk A/S

      2. 8.2.2 Sanofi Aventis

      3. 8.2.3 Eli Lilly

      4. 8.2.4 Astra Zeneca

      5. 8.2.5 Janssen Pharmaceuticals

      6. 8.2.6 Merck

      7. 8.2.7 Astellas

  9. 9. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The NORTH AMERICA DIABETES DRUGS Market market is studied from 2016 - 2027.

North America is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novo Nordisk, Abbott, Mylan, Sanofi, Eli Lilly are the major companies operating in NORTH AMERICA DIABETES DRUGS Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!